Trial Profile
Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab, 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma patients aged between 65 and 80 years
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Bortezomib; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms GEM2017FIT
- 12 Dec 2023 Primary endpoint has been met, (the MRD(-) rate (NGF 10-5) at the end of induction to compare both experimental arms, KRd and D-KRd to the control-one, VMP-Rd), as per Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Sep 2022 Planned End Date changed from 22 Oct 2031 to 1 Jan 2031.